Showing 1781-1790 of 2657 results for "".
- Prevent Blindness Releases Message to Eye Care Patients Regarding the COVID-19 Pandemichttps://modernod.com/news/prevent-blindness-releases-message-to-eye-care-patients-regarding-the-covid-19-pandemic/2477470/In response to the numerous queries from patients and caregivers, Prevent Blindness has issued the following statement in regards to eye care during the coronavirus pandemic. “For everyone’s health and s
- Orbis International Commences First-Ever Training Program in the United Stateshttps://modernod.com/news/orbis-international-commences-first-ever-training-program-in-the-united-states/2477368/Orbis International commenced its first-ever training program in the United States. Eye care professionals from Latin America have come to Texas for 2 weeks of training on board Orbis’s Flying
- Scientists Use Revolutionary Gene-Editing Tool to Edit Inside a Patienthttps://modernod.com/news/in-a-1st-scientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient/2477349/For the first time, scientists have used the gene-editing technique CRISPR to try to edit a gene while the DNA is still inside a person’s body, according to an NPR
- Microstent Reduces Post-Cataract Surgery Intraocular Pressure in Glaucoma Patientshttps://modernod.com/news/microstent-reduces-post-cataract-surgery-intraocular-pressure-in-glaucoma-patients/2477293/Microstent implantation in Schlemm’s canal reduces early postoperative IOP following cataract surgery in patients with mild or moderate glaucoma, according to findings from the HORIZON study of the Hydrus microstent, according to a Reuters
- Treat-and-Extend Approach With Ranibizumab Effective in AMDhttps://modernod.com/news/treat-and-extend-approach-with-ranibizumab-effective-in-amd/2477253/In patients with neovascular age-related macular disease, a treat-and-extend ranibizumab regimen is not inferior to injections given at fixed intervals, plus it’s more convenient, according to a new clinical trial, according to a Reuters
- RegeneRx JV Partner Updates on Strategic Dry Eye Discussionshttps://modernod.com/news/regenerx-jv-partner-updates-on-strategic-dry-eye-discussions/2477013/RegeneRx Biopharmaceuticals released a summary of its U.S. joint venture partner, GtreeBNT’s, recent attendance at the American Academy of Ophthalmology meeting (AAO) in San Francisco. The following summary was provided to RegeneRx by GtreeBNT and is posted
- SightGlass Vision to Present Pivotal Clinical Trial Baseline Data Evaluating Novel Lenses to Control Nearsightedness in Childrenhttps://modernod.com/news/sightglass-vision-to-present-pivotal-clinical-trial-baseline-data-evaluating-novel-lenses-to-control-nearsightedness-in-children/2476876/SightGlass Vision announced that baseline data from CYPRESS, the company’s pivotal trial assessing the safety and efficacy of novel lenses designed to control nearsightedness in children, will be presented at the 17th International Myopia Conference 2019, held
- EyecareLive Unveils Enhanced Responsible Telemedicine Platform for Optometry and Ophthalmologyhttps://modernod.com/news/eyecarelive-unveils-enhanced-responsible-telemedicine-platform-for-optometry-and-ophthalmology/2476674/EyecareLive announced the release of EyecareLive 2.0. EyecareLive was built by doctors, for doctors, with a mission to strengthen the doctor-patient relationship by providing a comprehensive telemedicine platform that enhances patient care. The launch will also feature EyecareLive’s
- Seniors With Vision Loss Experience Discrimination, Depressionhttps://modernod.com/news/seniors-with-vision-loss-experience-discrimination-depression/2476623/Seniors with declining vision are more likely than peers with good eyesight to experience discrimination as well as depression that may result from this bias, a new study from the UK suggests, according to a Reuters report. After s
- NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacinhttps://modernod.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the exten